BriefCase-Triage vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A provides a broad AI-powered triage solution for critical findings across various medical imaging modalities, enhancing general radiology workflows and supporting multiple specialties. In contrast, Tool B is a highly specialized AI screening tool focused exclusively on the early detection of cardiac amyloidosis from echocardiogram video clips. While both leverage AI for cardiology-related image analysis, their distinct scope and specific applications mean they address different clinical needs.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
BriefCase-Triage by Aidoc is an FDA-cleared AI solution designed to enhance radiology workflows by rapidly detecting and prioritizing critical findings across multiple indications in medical images. It serves specialties such as Cardiology, Emergency Medicine, Neurology, Oncology, Radiology, and Surgery. EchoGo Amyloidosis by Ultromics is an FDA-cleared AI-powered screening tool specifically for the early detection of cardiac amyloidosis from echocardiogram video clips, primarily focused on cardiology.
Aidoc's BriefCase-Triage analyzes various medical images, including CT exams with and without contrast that include the chest, abdomen, head, or ribs, to identify critical findings. Ultromics' EchoGo Amyloidosis specifically analyzes echocardiogram video clips to identify suspected cardiac amyloidosis.
BriefCase-Triage provides real-time alerts and notifications, prioritizing critical cases and offering a comprehensive triage solution for multiple indications. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on its automated analysis of echocardiographic markers like ventricular volume, cardiac function, and myocardial movement.
BriefCase-Triage aims for an order-of-magnitude reduction in false alerts and, in pivotal studies, has achieved a mean sensitivity of 97% (up to 98.5%) and a mean specificity of 98% (up to 99.7%) for its abdomen CT indications. EchoGo Amyloidosis reports high diagnostic accuracy with 85% sensitivity and 93% specificity, demonstrating consistent performance across cardiac amyloidosis subtypes (AL, wild-type ATTR, and variant ATTR).
BriefCase-Triage is FDA-cleared, HIPAA compliant, SOC2 compliant, and GDPR compliant. EchoGo Amyloidosis is FDA-cleared and HIPAA compliant, and has also received Breakthrough Device designation from the FDA.